ArticleAdvances in therapy2024

Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.

Gilles Salles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.